V. Khaitova

发表

High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV‐infected patients treated with sofosbuvir‐containing regimens

M. Woodward, A. Branch, D. Dieterich, 2016, Journal of viral hepatitis.

Serum and Ascites Chromogranin-A in Patients With Metastatic Neuroendocrine Tumors

T. Schiano, M. Kim, T. Curran, 2011, Pancreas.

Costs of telaprevir‐based triple therapy for hepatitis C: $189,000 per sustained virological response

A. Branch, V. Martel-Laferrière, A. Moskowitz, 2014, Hepatology.

An Escalating Dose Regimen of Pegylated Interferon and Ribavirin in HCV Cirrhotic Patients Referred for Liver Transplant

T. Schiano, E. Norkus, Charissa Y. Chang, 2009, Transplantation.

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.

A. Branch, S. Friedman, D. Dieterich, 2016, World journal of gastroenterology.

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

T. Schiano, P. Perumalswami, J. Doucette, 2015, World journal of gastroenterology.

795 REAL WORLD COSTS OF TELAPREVIR-BASED TRIPLE THERAPY, INCLUDING COSTS OF MANAGING ADVERSE EVENTS, AT THE MOUNT SINAI MEDICAL CENTER, NY: $147,000 PER EOT

A. Branch, V. Martel-Laferrière, D. Dieterich, 2013 .

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

A. Branch, V. Martel-Laferrière, D. Dieterich, 2017, World journal of hepatology.

Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid.

A. Branch, C. Rice, T. Schiano, 2011, Journal of virological methods.